Celldex Therapeutics is a biopharmaceutical company based in Branford, CT, specializing in the development of transformative antibody therapeutics. Their lead program, barzolvolimab, is a humanized monoclonal antibody inhibitor of KIT, targeting mast cells and offering potential treatment options for severe inflammatory, allergic, and autoimmune diseases.
Driven by their extensive experience in antibody-based immunotherapies, Celldex utilizes proprietary antibody programs and technologies to optimize the discovery and development of innovative scientific programs. They are committed to improving the lives of patients by targeting core pathological drivers of diseases and offering best-in-class treatment options.
Generated from the website